Martin Lydia, Lambert Raphaella, Hoadley Susan, Shadman Layla, Lee Raphael C
Plastic Surgery, The University of Chicago Medicine, Chicago, USA.
Plastic Surgery, Pritzker School of Medicine, Chicago, USA.
Cureus. 2024 Nov 25;16(11):e74412. doi: 10.7759/cureus.74412. eCollection 2024 Nov.
Benign lipomas are a common medical problem that is not known to regress spontaneously. In addition, vitamin D (VD) is a known regulator of adipocyte proliferation and differentiation. Thus, the purpose of this multi-case study was to determine if optimizing serum 1,25(OH)D3 (VD3) concentrations to the 40-60 ng/mL range would catalyze regression of benign subcutaneous lipomas. This IRB-approved study was interrupted by the COVID-19 epidemic. Nine patients presenting to the plastic surgery clinic before the pandemic and who followed up after defined the study cohort. Patients underwent lipoma size measurement and serum 25(OH)D (VD) assay at the clinic visit before and after the pandemic. Enrolled patients were prescribed 10,000 IU of VD3 intake daily for three months if serum VD levels were abnormally low and then 5,000 IU daily thereafter. Patients were prescribed 5,000 IU daily if serum VD levels were within a normal (30-40 ng/dL) range. The treatment duration was seven to 18 months. Of the nine patients who were compliant with oral VD3 intake and exhibited increased serum VD levels, six manifested substantial lipoma size regression, and three manifested lipoma growth arrest. Serum VD levels increased in all (nine) patients compliant with VD3 treatment. Although limited in size, this study suggests that VD3 therapy possibly promotes lipoma regression and should be further investigated.
良性脂肪瘤是一种常见的医学问题，目前尚不清楚其是否会自发消退。此外，维生素D（VD）是已知的脂肪细胞增殖和分化调节剂。因此，本多病例研究的目的是确定将血清1,25(OH)D3（VD3）浓度优化至40 - 60 ng/mL范围是否会促使良性皮下脂肪瘤消退。这项经机构审查委员会批准的研究因新冠疫情而中断。九名在疫情大流行之前到整形外科诊所就诊并在之后进行随访的患者构成了研究队列。患者在疫情大流行前后的诊所就诊时接受了脂肪瘤大小测量和血清25(OH)D（VD）检测。如果血清VD水平异常低，入组患者每天服用10,000 IU的VD3，持续三个月，之后每天服用5,000 IU。如果血清VD水平在正常范围（30 - 40 ng/dL）内，患者每天服用5,000 IU。治疗持续时间为7至18个月。在九名依从口服VD3摄入且血清VD水平升高的患者中，六名患者的脂肪瘤大小显著消退，三名患者的脂肪瘤生长停滞。所有（九名）依从VD3治疗的患者血清VD水平均升高。尽管本研究规模有限，但表明VD3治疗可能促进脂肪瘤消退，应进一步研究。
